MX2013012393A - Anticuerpos anti-receptor tipo proteina-tirosina-fosfatasa sigma humano. - Google Patents

Anticuerpos anti-receptor tipo proteina-tirosina-fosfatasa sigma humano.

Info

Publication number
MX2013012393A
MX2013012393A MX2013012393A MX2013012393A MX2013012393A MX 2013012393 A MX2013012393 A MX 2013012393A MX 2013012393 A MX2013012393 A MX 2013012393A MX 2013012393 A MX2013012393 A MX 2013012393A MX 2013012393 A MX2013012393 A MX 2013012393A
Authority
MX
Mexico
Prior art keywords
protein tyrosine
type protein
tyrosine phosphatase
antibody
human receptor
Prior art date
Application number
MX2013012393A
Other languages
English (en)
Other versions
MX352599B (es
Inventor
Tomohide Yamazaki
Jing Zhao
Koji Ishida
Mayuki Endo
Yasue Shibata
Minkwon Cho
Original Assignee
Sbi Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sbi Biotech Co Ltd filed Critical Sbi Biotech Co Ltd
Publication of MX2013012393A publication Critical patent/MX2013012393A/es
Publication of MX352599B publication Critical patent/MX352599B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Mycology (AREA)

Abstract

Un anticuerpo monoclonal que se une a un dominio extracelular de proteína-tirosina-fosfatasa s tipo receptor de humano (PTPRS humano) o fragmento que incluye una región de unión al antígeno del mismo.
MX2013012393A 2011-04-28 2012-04-27 Anticuerpos anti-receptor tipo proteina-tirosina-fosfatasa sigma humano. MX352599B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011101752 2011-04-28
PCT/JP2012/061795 WO2012148003A1 (en) 2011-04-28 2012-04-27 ANTI-HUMAN RECEPTOR-TYPE PROTEIN TYROSINE PHOSPHATASE σ ANTIBODY

Publications (2)

Publication Number Publication Date
MX2013012393A true MX2013012393A (es) 2014-04-30
MX352599B MX352599B (es) 2017-11-30

Family

ID=46147004

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013012393A MX352599B (es) 2011-04-28 2012-04-27 Anticuerpos anti-receptor tipo proteina-tirosina-fosfatasa sigma humano.

Country Status (17)

Country Link
US (2) US9803026B2 (es)
EP (2) EP3232202B1 (es)
JP (2) JP6001557B2 (es)
KR (1) KR101873614B1 (es)
CN (1) CN103703372B (es)
AU (2) AU2012248158C1 (es)
BR (1) BR112013027631A2 (es)
CA (1) CA2834243C (es)
ES (2) ES2638088T3 (es)
HU (2) HUE054211T2 (es)
IL (1) IL229127A (es)
MX (1) MX352599B (es)
PL (2) PL3232202T3 (es)
PT (2) PT3232202T (es)
RU (2) RU2715642C2 (es)
SG (3) SG10202108240VA (es)
WO (1) WO2012148003A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8158757B2 (en) 2007-07-02 2012-04-17 Oncomed Pharmaceuticals, Inc. Compositions and methods for treating and diagnosing cancer
WO2012148003A1 (en) * 2011-04-28 2012-11-01 Sbi Biotech Co., Ltd. ANTI-HUMAN RECEPTOR-TYPE PROTEIN TYROSINE PHOSPHATASE σ ANTIBODY
CN106167526A (zh) 2011-07-15 2016-11-30 昂考梅德药品有限公司 Rspo结合剂和其应用
MX2015000565A (es) 2012-07-13 2015-04-10 Oncomed Pharm Inc Agentes de union de proteina de r-espondina humana (rspo3) y usos de los mismos.
US20150175979A1 (en) 2012-07-23 2015-06-25 La Jolla Institute For Allergy And Immunology Ptprs and proteoglycans in autoimmune disease
US11160873B2 (en) * 2014-02-04 2021-11-02 Monash University Anti-metalloprotease antibody for diagnosis and treatment of cancers
WO2015117199A1 (en) * 2014-02-04 2015-08-13 Monash University Anti-metalloprotease antibody for diagnosis and treatment of cancers
CA2961374A1 (en) 2014-09-16 2016-03-24 Oncomed Pharmaceuticals, Inc. Treatment of fibrotic diseases
EP3633371A1 (en) * 2014-12-18 2020-04-08 F. Hoffmann-La Roche AG Assay and method for determining cdc eliciting antibodies
JP7251792B2 (ja) * 2017-03-23 2023-04-04 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 抗Ｃ５ａ抗体とその使用
CA3057676A1 (en) * 2017-03-24 2018-09-27 The Regents Of The University Of California Proteoglycan irregularities in abnormal fibroblasts and therapies based therefrom
US11242398B2 (en) 2017-08-01 2022-02-08 Remd Biotherapeutics, Inc. Anti-OX40 antibodies and methods of activating OX40
WO2020023679A1 (en) * 2018-07-25 2020-01-30 Accurus Biosciences, Inc. Novel cldn 18.2-specific monoclonal antibodies and methods of use thereof
MX2022004058A (es) * 2019-10-04 2022-07-13 Albert Einstein College Of Medicine Kir3dl3 es un receptor inhibidor del sistema inmunitario y usos del mismo.
CN114426582B (zh) * 2022-01-07 2022-11-25 陕西脉元生物科技有限公司 一种神经特异性烯醇化酶单克隆抗体及其制备方法和应用
CN116041526B (zh) * 2022-11-14 2023-09-29 华中农业大学 一种鼠抗草鱼IgT单克隆抗体及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7847494A (en) 1993-10-01 1995-05-01 New York University Novel receptor-type phosphotyrosine phosphatase-sigma
AU2003252328A1 (en) 2002-08-01 2004-02-23 Ginkgo Biomedical Research Institute Co., Ltd. Method of detecting mouse interferon-producing cells
US7435590B2 (en) * 2003-03-14 2008-10-14 Taisho Pharmaceutical Co., Ltd. Monoclonal antibody and hybridoma producing the same
US8038996B2 (en) 2004-03-27 2011-10-18 University Of Arizona Composition and method for cancer treatment
US20080008719A1 (en) 2004-07-10 2008-01-10 Bowdish Katherine S Methods and compositions for the treatment of prostate cancer
EP1928916A2 (en) 2005-09-29 2008-06-11 Viral Logic Systems Technology Corp. Immunomodulatory compositions and uses therefor
WO2009003274A1 (en) * 2007-06-29 2009-01-08 The Hospital For Sick Children Susceptibility gene for inflammatory bowel disease
US20110287034A1 (en) * 2008-11-14 2011-11-24 The Brigham And Womens Hospital, Inc. Therapeutic and diagnostic methods relating to cancer stem cells
US20120231014A1 (en) * 2009-08-18 2012-09-13 Case Western Reserve University Neural Regeneration
WO2011097327A2 (en) * 2010-02-02 2011-08-11 La Jolla Institute For Allergy & Immunology Compositions and methods of modulating receptor protein tyrosine phosphatases
WO2012148003A1 (en) * 2011-04-28 2012-11-01 Sbi Biotech Co., Ltd. ANTI-HUMAN RECEPTOR-TYPE PROTEIN TYROSINE PHOSPHATASE σ ANTIBODY

Also Published As

Publication number Publication date
AU2016262677A1 (en) 2016-12-08
US20180155446A1 (en) 2018-06-07
JP6412072B2 (ja) 2018-10-24
AU2012248158C1 (en) 2017-02-02
EP2702412B1 (en) 2017-07-26
AU2016262677B2 (en) 2018-08-30
HUE054211T2 (hu) 2021-08-30
WO2012148003A1 (en) 2012-11-01
CN103703372B (zh) 2018-01-26
MX352599B (es) 2017-11-30
EP2702412A1 (en) 2014-03-05
JP6001557B2 (ja) 2016-10-05
IL229127A (en) 2017-11-30
US10730955B2 (en) 2020-08-04
RU2715642C2 (ru) 2020-03-02
JP2017048183A (ja) 2017-03-09
IL229127A0 (en) 2013-12-31
RU2017118262A3 (es) 2018-11-02
EP3232202B1 (en) 2020-02-19
AU2012248158A1 (en) 2014-01-30
AU2012248158B2 (en) 2016-09-08
PL2702412T3 (pl) 2018-01-31
HUE034752T2 (en) 2018-02-28
KR101873614B1 (ko) 2018-07-02
PT2702412T (pt) 2017-11-02
BR112013027631A2 (pt) 2022-01-04
ES2788183T3 (es) 2020-10-20
US9803026B2 (en) 2017-10-31
RU2017118262A (ru) 2018-11-02
SG10202108240VA (en) 2021-09-29
PL3232202T3 (pl) 2020-10-05
CA2834243C (en) 2019-08-27
ES2638088T3 (es) 2017-10-18
CA2834243A1 (en) 2012-11-01
PT3232202T (pt) 2020-05-22
KR20140033024A (ko) 2014-03-17
CN103703372A (zh) 2014-04-02
RU2013152816A (ru) 2015-06-10
US20140127223A1 (en) 2014-05-08
EP3232202A1 (en) 2017-10-18
SG194614A1 (en) 2013-12-30
JP2014524733A (ja) 2014-09-25
SG10201503257WA (en) 2015-06-29

Similar Documents

Publication Publication Date Title
MX352599B (es) Anticuerpos anti-receptor tipo proteina-tirosina-fosfatasa sigma humano.
PH12017502161A1 (en) Anti-cd40 antibodies and uses thereof
CY1120181T1 (el) Αντι-cd40 αντισωματα
MX2022002364A (es) Anticuerpos anti-pd-l1.
NI201400019A (es) Anticuerpo anti-alfabetatcr
EP3702372A3 (en) Anti-cd40 human antibodies
EA201592213A1 (ru) Антитела антирецептор трансферрина и способы их использования
CR20140146A (es) Anticuerpos anti-cd134 (ox40) y usos de los mismos
GT201300233A (es) Receptores de celulas t similares a anticuerpos especificos para un peptido wt1 presentado por hla-a2
BR112016000666A2 (pt) Constructos de ligação de antígeno cd3 e cd19 biespecíficos
EA201391540A1 (ru) Агонисты fgfr1 и способы их применения
EA201791693A1 (ru) Гетеродимерные иммуноглобулины
MX2014000363A (es) Anticuerpos monoclonales inhibidores anti-factor xii-xiia.
EA201990672A1 (ru) Антитела, специфически связывающиеся с pd-1, и их функциональные фрагменты
WO2013115410A3 (en) Anti-phospholipase d4 antibody
EA201491107A1 (ru) Антитела к рецептору эпидермального фактора роста 3 (her3), направленные на домен ii her3
TN2015000277A1 (en) Bmp-6 antibodies
PH12015501650A1 (en) Human antibody specific to human metapneumovirus, or antigen-binding fragment thereof
GB201207155D0 (en) Antibodies
SG11201810779PA (en) Method for screening antibody using patient-derived tumor spheroids
UA111372C2 (uk) ФРАГМЕНТ Fab' АНТИТІЛА ПРОТИ NGF ЛЮДИНИ
CR20150351A (es) Proteinas de union al antígeno bcma
TH142231A (th) แอนตี้บอดี้สำหรับรีเซพเตอร์ 3 ของปัจจัยการเจริญเติบโตของหนังกำพร้า (her3)

Legal Events

Date Code Title Description
FG Grant or registration